Overcoming osimertinib resistance with AKT inhibition in EGFRm-driven Non-Small-Cell-Lung-Cancer with PIK3CA/PTEN alterations

CONCLUSIONS: Together, this approach offers a potential treatment strategy for patients with EGFRm-driven NSCLC that have a sub-optimal response, or develop resistance, to osimertinib through PIK3CA/AKT/PTEN alterations.PMID:38630555 | DOI:10.1158/1078-0432.CCR-23-2540

Source: Cancer Control - April 17, 2024 Category: Cancer & Oncology Authors: Ursula Grazini Aleksandra Markovets Lucy Ireland Daniel O'Neill Benjamin Phillips Man Xu Matthias Pfeifer Tereza Vaclova Matthew J Martin Ludovic Bigot Luc Friboulet Ryan Hartmaier Maria Emanuela Cuomo Simon T Barry Paul D Smith Nicolas Floc'h Source Type: research